|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 5,993,856
Overview
United States Patent 5,993,856, granted on November 30, 1999, to Hoffmann-La Roche Inc., covers a class of compounds and methods related to their use as inhibitors of β-secretase (BACE1), a key enzyme in amyloid-beta production implicated in Alzheimer's disease. The patent claims a specific chemical scaffold with defined substituents and the methods of synthesizing and using these compounds.
What is the scope of U.S. Patent 5,993,856?
The patent broadly protects:
- A class of β-secretase inhibitors based on a core chemical structure, specifically, a 2-aminopyridine derivative.
- Substituted variants where specific groups are attached to the core for enhanced activity.
- Methods of inhibiting β-secretase enzymatic activity.
- Pharmaceutical compositions containing these compounds for treating Alzheimer's disease.
It does not cover all BACE1 inhibitors; rather, it claims specific compounds within a chemical class.
What are the key claims of U.S. Patent 5,993,856?
The patent includes 29 claims, with the independent claims focusing on:
-
Claim 1: A compound characterized as a 2-aminopyridine derivative with various possible substituents attached at specified positions, designed to inhibit β-secretase.
-
Claims 2–9: Variations of the compound's substituents, including differing aromatic and heteroaromatic groups, stereochemistry, and further modifications.
-
Claims 10–20: Methods of synthesizing the compounds, involving specific chemical reactions and intermediates.
-
Claims 21–29: Pharmaceutical formulations, including tablets, injections, and methods of treatment, emphasizing the use of these compounds for inhibiting β-secretase in mammals.
The core chemical theme involves the 2-aminopyridine moiety linked to various side chains, serving as a scaffold for activity.
Patent Landscape Analysis
Pre-Patent Landscape (Prior Art)
Prior to 1999, several classes of compounds targeting β-secretase were known, including:
- Hydroxyethylamines
- Oxyhydrazides
- Various peptide-like structures
Some early patents included inhibitors with similar motifs, but none explicitly claimed the particular 2-aminopyridine scaffold.
Patents Filed Post-Patent 5,993,856
Post-1999, numerous patents have emerged on BACE1 inhibitors, reflecting the drug development interest in Alzheimer's therapeutics. These include:
- Shire's BACE inhibitors
- Molecular biotech companies’ integrated inhibitor portfolios
- Later patents extended claims to more diverse heterocycles, optimized pharmacokinetics, and improved brain penetration
Examples include patent filings from Merck, Novartis, and Biohaven, often building on the chemical space covered by the 5,993,856 patent but expanding to other scaffolds such as azaheterocycles and aminoimidazoles.
Patent Expiry and Freedom to Operate
- The patent was filed in 1998 and granted in 1999, with a typical 20-year patent term expiring in 2019.
- Some related patents, such as process patents, remain active or have been extended based on patent term adjustments or new filings.
Patent Families and Related Patents
The original patent is part of a patent family covering:
- Chemical compounds with various substitutions
- Methods of synthesis and purification
- Therapeutic applications for Alzheimer's disease
Other patents often cite U.S. 5,993,856, indicating its influence on subsequent drug discovery.
Implications for R&D and Commercial Development
- The patent provided significant breadth for a specific class of BACE inhibitors, encouraging research into similar compounds.
- Its expiration opens opportunities for third-party development, biosimilar compounds, or design-around strategies.
- Generic versions or related compounds may use different chemical scaffolds to avoid infringement.
Summary of Specifics
| Aspect |
Details |
| Chemical class |
2-Aminopyridine derivatives |
| Key claim features |
Variable substituents on pyridine core, method of synthesis, use |
| Patent lifespan |
Filed: 1998, Issued: 1999, Expired: 2019 |
| Expiry implications |
Increased freedom for generic development, patent clearance needed |
| Post-issue filings |
Numerous patents around heterocycle BACE inhibitors, pharmacokinetic optimization |
Key Takeaways
- U.S. Patent 5,993,856 claims a specific class of 2-aminopyridine derivatives as BACE1 inhibitors for Alzheimer's therapy.
- Its scope includes chemical structures, synthesis methods, and therapeutic applications.
- The patent landscape post-2019 shows active innovation around alternative scaffolds, pharmacokinetics, and brain penetration.
- The patent's expiration permits broader experimentation, licensing, or development by third parties.
FAQs
-
Does U.S. Patent 5,993,856 still block competitors?
No. It expired in 2019, removing patent protection for the claimed compounds.
-
Are the compounds in the patent still relevant for Alzheimer’s treatment development?
Yes, as they laid the groundwork for BACE1 inhibitors, though newer compounds with improved profiles are being developed.
-
Can a new BACE inhibitor be developed without infringing the expired patent?
Yes. Developers can focus on different chemical scaffolds or modifications not covered by the original claims.
-
Does the patent cover oral or injectable formulations?
The patent claims encompass both, including specific pharmaceutical compositions.
-
What are the key considerations for patent landscapes around BACE inhibitors?
Focus on scaffold diversity, pharmacokinetic properties, brain penetration, and synthesis methods, to avoid infringement or develop novel compounds.
References:
- U.S. Patent 5,993,856.
- Patent landscape analyses published by various patent offices and biotechnology intelligence reports.
- Scientific publications on BACE1 inhibitors and their development timelines.
More… ↓
⤷ Start Trial
|
